PHARMABCINE INC
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
PharmAbcine Announces Safety Approval for 4mg Single-dose Cohort in Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration 2024-10-15 09:51
PharmAbcine's Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration Advances to Both Single-dose of 4mg and Multiple-dose of 3mg 2024-07-02 11:02
PharmAbcine's U.S. Subsidiary, Wincal Biopharm, Presented Preclinical Data on Eye Drops from its Proprietary OPC Platform at ARVO 2024 2024-05-23 08:51
PharmAbcine's U.S. Subsidiary, Wincal Biopharm, to Present Preclinical Data from its Proprietary OPC Platform Targeting Ocular Diseases at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2024 2024-04-23 07:25
PharmAbcine Announces First Patient Dosed in Phase 1a/b Clinical Trial of PMC-309 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced or Metastatic Solid Tumors 2024-01-24 10:01
PharmAbcine Publishes Study in Science Advances Demonstrating the Potential of PMC-403 in Preclinical Models of Idiopathic Systemic Capillary Leak Syndrome 2023-11-23 10:31
PharmAbcine Receives Safety Review Committee Approval to Advance to Dose Level 2 of Clinical Trial of PMC-403 with Neovascular Age-related Macular Degeneration following Dose Level 1 Safety Data 2023-11-09 21:00
PharmAbcine Announces First Patient Dosed in the Phase I Clinical Trial of Its Novel TIE2 Agonistic Antibody in nAMD 2023-07-26 20:00
PharmAbcine Receives IND Approval from the Korean MFDS for Phase I Clinical Trial of Its Novel TIE2 Agonistic Antibody in nAMD 2023-05-23 20:00
PharmAbcine to participate in "BIO International Convention 2023" 2023-05-08 20:00
PharmAbcine Announces Collaboration Agreement with MSD to Evaluate Anti-VISTA Antibody PMC-309 in Combination with KEYTRUDA® (pembrolizumab) 2022-12-12 21:00
PharmAbcine to Participate in the 41th Annual J.P. Morgan Healthcare Conference and Biotech Showcase™ 2023 during JPM Week 2022-12-08 21:00
PharmAbcine Announces Poster Presentations on Its anti-VISTA Antibody Candidate at SITC 2022 2022-10-17 20:00
PharmAbcine to Participate in BIO-Europe 2022 2022-09-26 20:00
PharmAbcine to participate in Jefferies Global Healthcare Conference and BIO International Convention 2022-05-11 20:00
PharmAbcine Announces Positive Results for Its Novel TIE2-Activating Antibody in GLP Toxicology Study 2022-04-26 20:30
PharmAbcine Strengthens Scientific Advisory Board with a World-Renowned Expert in Ophthalmology 2022-04-26 20:00
PharmAbcine Presents Updated Preclinical Data of Its Anti-VISTA Antibody Candidate at AACR 2022 2022-04-11 20:00
RNAGENE Signs a Collaborative Research Agreement with PharmAbcine to Develop Novel mRNA Therapeutics 2022-03-21 20:00
NuclixBio Announces a Collaborative Research Agreement with PharmAbcine 2022-03-14 20:00
1 2 3